Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study

To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients. This retrospective study utilized data from the 2017 US National Health and...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2021-03, Vol.37 (3), p.443-457
Main Authors: Foster, Shonda A., Balkaran, Bridget L., Cambron-Mellott, M. Janelle, Samaan, Karen, Mason, Oksana, Ye, Wenyu, Rowland, John C., Jaffe, Dena H.
Format: Article
Language:English
Subjects:
Claims
migraine
monthly headache days
National Health and Wellness Survey
prevention-eligible
preventive therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c413t-5d31b091ebacbaa99f40aaeb252daa18eccd7e79b2ccfaadbba71a42371aa1f3
cites cdi_FETCH-LOGICAL-c413t-5d31b091ebacbaa99f40aaeb252daa18eccd7e79b2ccfaadbba71a42371aa1f3
container_end_page 457
container_issue 3
container_start_page 443
container_title Current medical research and opinion
container_volume 37
creator Foster, Shonda A.
Balkaran, Bridget L.
Cambron-Mellott, M. Janelle
Samaan, Karen
Mason, Oksana
Ye, Wenyu
Rowland, John C.
Jaffe, Dena H.
description To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients. This retrospective study utilized data from the 2017 US National Health and Wellness Survey linked with medical and pharmacy claims. Patients aged ≥18 years who self-reported experiencing migraine and had confirmed evidence of migraine (≥1 medical or pharmacy claim) were included. Prevention eligibility was based on number of headache days in the past 30 days (prevention-eligible: ≥4 and prevention non-eligible:
doi_str_mv 10.1080/03007995.2020.1865749
format article
fullrecord <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_miscellaneous_2470902511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2470902511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-5d31b091ebacbaa99f40aaeb252daa18eccd7e79b2ccfaadbba71a42371aa1f3</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EotvCTwD5yCXFdhIccwIVKEiVemh7tsb2pGtInGA7W-3v6R_FYbccmYNHGn_vvcMj5A1n55x17D2rGZNKteeCiXLqPrSyUc_IhjeyrppOyudkszLVCp2Q05R-MsZFp9RLclKX4YK1G_L4BcfpPsK89ZZCcNQOPngLA7VbiGAzRp-yt4lOPZ0j7jBkP4UKB3_vzYB0huzLLdEHn7d09MXLB6Q-0LxFenfzkQItlr_Q0QCrtFinJe5w_zcO3FjyUo7lb4clHfyYqIMMBhLSlBe3f0Ve9DAkfH3cZ-T229fbi-_V1fXlj4vPV5VteJ2r1tXcMMXRgDUASvUNA0AjWuEAeIfWOolSGWFtD-CMAcmhEXV5gff1GXl3sJ3j9HvBlPXok8VhgIDTkrRoJFNMtJwXtD2gNk4pRez1HP0Ica8502s9-qkevdajj_UU3dtjxGJGdP9UT30U4NMB8KGf4ggPUxyczrAfpthHCNYnXf8_4w94RaTl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2470902511</pqid></control><display><type>article</type><title>Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Foster, Shonda A. ; Balkaran, Bridget L. ; Cambron-Mellott, M. Janelle ; Samaan, Karen ; Mason, Oksana ; Ye, Wenyu ; Rowland, John C. ; Jaffe, Dena H.</creator><creatorcontrib>Foster, Shonda A. ; Balkaran, Bridget L. ; Cambron-Mellott, M. Janelle ; Samaan, Karen ; Mason, Oksana ; Ye, Wenyu ; Rowland, John C. ; Jaffe, Dena H.</creatorcontrib><description>To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients. This retrospective study utilized data from the 2017 US National Health and Wellness Survey linked with medical and pharmacy claims. Patients aged ≥18 years who self-reported experiencing migraine and had confirmed evidence of migraine (≥1 medical or pharmacy claim) were included. Prevention eligibility was based on number of headache days in the past 30 days (prevention-eligible: ≥4 and prevention non-eligible: &lt;4). Descriptive statistics summarized study variables; bivariate and multivariable analyses were conducted to examine the association of prevention-eligibility status with outcomes. Analyses included 450 patients, 291 (65%) prevention-eligible, and of these 56 (19%) received preventive therapy. Overall, patients were 42.98 ± 14.51 years old; 84% were female. Prevention-eligible patients reported significantly more migraine headache days in the past 6 months (29.27 ± 37.96 vs. 8.61 ± 7.88), had lower mental component summary scores (35.80 ± 2.73 vs. 37.90 ± 2.96), and more presenteeism (47.30 ± 2.98% vs. 37.90 ± 2.60%), overall work impairment (46.30 ± 2.87% vs. 37.90 ± 2.55%) and activity days missed due to migraine (8.16 ± 3.05 vs. 3.82 ± 1.58) than prevention non-eligible patients (all p&lt;.001). Prevention-eligible patients receiving preventive therapy reported more migraine headache days during the past month (9.21 ± 7.99 vs. 6.06 ± 7.10; p=.002) and activity days lost due to migraine (18.39 ± 28.08 vs. 10.69 ± 21.43, p=.015) than those not receiving preventive therapy. Prevention-eligible patients experience greater burden due to migraine, including more headache days, worse health-related quality-of-life, and greater work and activity impairment than prevention non-eligible patients.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1080/03007995.2020.1865749</identifier><identifier>PMID: 33331205</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Claims ; migraine ; monthly headache days ; National Health and Wellness Survey ; prevention-eligible ; preventive therapy</subject><ispartof>Current medical research and opinion, 2021-03, Vol.37 (3), p.443-457</ispartof><rights>2021 Eli Lilly and Company. Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-5d31b091ebacbaa99f40aaeb252daa18eccd7e79b2ccfaadbba71a42371aa1f3</citedby><cites>FETCH-LOGICAL-c413t-5d31b091ebacbaa99f40aaeb252daa18eccd7e79b2ccfaadbba71a42371aa1f3</cites><orcidid>0000-0002-4478-7840 ; 0000-0003-0061-104X ; 0000-0003-2780-9232 ; 0000-0001-5134-037X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33331205$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Foster, Shonda A.</creatorcontrib><creatorcontrib>Balkaran, Bridget L.</creatorcontrib><creatorcontrib>Cambron-Mellott, M. Janelle</creatorcontrib><creatorcontrib>Samaan, Karen</creatorcontrib><creatorcontrib>Mason, Oksana</creatorcontrib><creatorcontrib>Ye, Wenyu</creatorcontrib><creatorcontrib>Rowland, John C.</creatorcontrib><creatorcontrib>Jaffe, Dena H.</creatorcontrib><title>Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients. This retrospective study utilized data from the 2017 US National Health and Wellness Survey linked with medical and pharmacy claims. Patients aged ≥18 years who self-reported experiencing migraine and had confirmed evidence of migraine (≥1 medical or pharmacy claim) were included. Prevention eligibility was based on number of headache days in the past 30 days (prevention-eligible: ≥4 and prevention non-eligible: &lt;4). Descriptive statistics summarized study variables; bivariate and multivariable analyses were conducted to examine the association of prevention-eligibility status with outcomes. Analyses included 450 patients, 291 (65%) prevention-eligible, and of these 56 (19%) received preventive therapy. Overall, patients were 42.98 ± 14.51 years old; 84% were female. Prevention-eligible patients reported significantly more migraine headache days in the past 6 months (29.27 ± 37.96 vs. 8.61 ± 7.88), had lower mental component summary scores (35.80 ± 2.73 vs. 37.90 ± 2.96), and more presenteeism (47.30 ± 2.98% vs. 37.90 ± 2.60%), overall work impairment (46.30 ± 2.87% vs. 37.90 ± 2.55%) and activity days missed due to migraine (8.16 ± 3.05 vs. 3.82 ± 1.58) than prevention non-eligible patients (all p&lt;.001). Prevention-eligible patients receiving preventive therapy reported more migraine headache days during the past month (9.21 ± 7.99 vs. 6.06 ± 7.10; p=.002) and activity days lost due to migraine (18.39 ± 28.08 vs. 10.69 ± 21.43, p=.015) than those not receiving preventive therapy. Prevention-eligible patients experience greater burden due to migraine, including more headache days, worse health-related quality-of-life, and greater work and activity impairment than prevention non-eligible patients.</description><subject>Claims</subject><subject>migraine</subject><subject>monthly headache days</subject><subject>National Health and Wellness Survey</subject><subject>prevention-eligible</subject><subject>preventive therapy</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNp9kUFv1DAQhS0EotvCTwD5yCXFdhIccwIVKEiVemh7tsb2pGtInGA7W-3v6R_FYbccmYNHGn_vvcMj5A1n55x17D2rGZNKteeCiXLqPrSyUc_IhjeyrppOyudkszLVCp2Q05R-MsZFp9RLclKX4YK1G_L4BcfpPsK89ZZCcNQOPngLA7VbiGAzRp-yt4lOPZ0j7jBkP4UKB3_vzYB0huzLLdEHn7d09MXLB6Q-0LxFenfzkQItlr_Q0QCrtFinJe5w_zcO3FjyUo7lb4clHfyYqIMMBhLSlBe3f0Ve9DAkfH3cZ-T229fbi-_V1fXlj4vPV5VteJ2r1tXcMMXRgDUASvUNA0AjWuEAeIfWOolSGWFtD-CMAcmhEXV5gff1GXl3sJ3j9HvBlPXok8VhgIDTkrRoJFNMtJwXtD2gNk4pRez1HP0Ica8502s9-qkevdajj_UU3dtjxGJGdP9UT30U4NMB8KGf4ggPUxyczrAfpthHCNYnXf8_4w94RaTl</recordid><startdate>20210304</startdate><enddate>20210304</enddate><creator>Foster, Shonda A.</creator><creator>Balkaran, Bridget L.</creator><creator>Cambron-Mellott, M. Janelle</creator><creator>Samaan, Karen</creator><creator>Mason, Oksana</creator><creator>Ye, Wenyu</creator><creator>Rowland, John C.</creator><creator>Jaffe, Dena H.</creator><general>Taylor &amp; Francis</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4478-7840</orcidid><orcidid>https://orcid.org/0000-0003-0061-104X</orcidid><orcidid>https://orcid.org/0000-0003-2780-9232</orcidid><orcidid>https://orcid.org/0000-0001-5134-037X</orcidid></search><sort><creationdate>20210304</creationdate><title>Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study</title><author>Foster, Shonda A. ; Balkaran, Bridget L. ; Cambron-Mellott, M. Janelle ; Samaan, Karen ; Mason, Oksana ; Ye, Wenyu ; Rowland, John C. ; Jaffe, Dena H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-5d31b091ebacbaa99f40aaeb252daa18eccd7e79b2ccfaadbba71a42371aa1f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Claims</topic><topic>migraine</topic><topic>monthly headache days</topic><topic>National Health and Wellness Survey</topic><topic>prevention-eligible</topic><topic>preventive therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Foster, Shonda A.</creatorcontrib><creatorcontrib>Balkaran, Bridget L.</creatorcontrib><creatorcontrib>Cambron-Mellott, M. Janelle</creatorcontrib><creatorcontrib>Samaan, Karen</creatorcontrib><creatorcontrib>Mason, Oksana</creatorcontrib><creatorcontrib>Ye, Wenyu</creatorcontrib><creatorcontrib>Rowland, John C.</creatorcontrib><creatorcontrib>Jaffe, Dena H.</creatorcontrib><collection>Taylor &amp; Francis Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Foster, Shonda A.</au><au>Balkaran, Bridget L.</au><au>Cambron-Mellott, M. Janelle</au><au>Samaan, Karen</au><au>Mason, Oksana</au><au>Ye, Wenyu</au><au>Rowland, John C.</au><au>Jaffe, Dena H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2021-03-04</date><risdate>2021</risdate><volume>37</volume><issue>3</issue><spage>443</spage><epage>457</epage><pages>443-457</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><abstract>To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients. This retrospective study utilized data from the 2017 US National Health and Wellness Survey linked with medical and pharmacy claims. Patients aged ≥18 years who self-reported experiencing migraine and had confirmed evidence of migraine (≥1 medical or pharmacy claim) were included. Prevention eligibility was based on number of headache days in the past 30 days (prevention-eligible: ≥4 and prevention non-eligible: &lt;4). Descriptive statistics summarized study variables; bivariate and multivariable analyses were conducted to examine the association of prevention-eligibility status with outcomes. Analyses included 450 patients, 291 (65%) prevention-eligible, and of these 56 (19%) received preventive therapy. Overall, patients were 42.98 ± 14.51 years old; 84% were female. Prevention-eligible patients reported significantly more migraine headache days in the past 6 months (29.27 ± 37.96 vs. 8.61 ± 7.88), had lower mental component summary scores (35.80 ± 2.73 vs. 37.90 ± 2.96), and more presenteeism (47.30 ± 2.98% vs. 37.90 ± 2.60%), overall work impairment (46.30 ± 2.87% vs. 37.90 ± 2.55%) and activity days missed due to migraine (8.16 ± 3.05 vs. 3.82 ± 1.58) than prevention non-eligible patients (all p&lt;.001). Prevention-eligible patients receiving preventive therapy reported more migraine headache days during the past month (9.21 ± 7.99 vs. 6.06 ± 7.10; p=.002) and activity days lost due to migraine (18.39 ± 28.08 vs. 10.69 ± 21.43, p=.015) than those not receiving preventive therapy. Prevention-eligible patients experience greater burden due to migraine, including more headache days, worse health-related quality-of-life, and greater work and activity impairment than prevention non-eligible patients.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>33331205</pmid><doi>10.1080/03007995.2020.1865749</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-4478-7840</orcidid><orcidid>https://orcid.org/0000-0003-0061-104X</orcidid><orcidid>https://orcid.org/0000-0003-2780-9232</orcidid><orcidid>https://orcid.org/0000-0001-5134-037X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0300-7995
ispartof Current medical research and opinion, 2021-03, Vol.37 (3), p.443-457
issn 0300-7995
1473-4877
language eng
recordid cdi_proquest_miscellaneous_2470902511
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Claims
migraine
monthly headache days
National Health and Wellness Survey
prevention-eligible
preventive therapy
title Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A45%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Demographic%20and%20clinical%20characteristics%20of%20prevention-eligible%20patients%20with%20migraine%20in%20the%20US:%20a%20linked%20national%20survey%20and%20administrative%20claims%20database%20study&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Foster,%20Shonda%20A.&rft.date=2021-03-04&rft.volume=37&rft.issue=3&rft.spage=443&rft.epage=457&rft.pages=443-457&rft.issn=0300-7995&rft.eissn=1473-4877&rft_id=info:doi/10.1080/03007995.2020.1865749&rft_dat=%3Cproquest_infor%3E2470902511%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c413t-5d31b091ebacbaa99f40aaeb252daa18eccd7e79b2ccfaadbba71a42371aa1f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2470902511&rft_id=info:pmid/33331205&rfr_iscdi=true